Author + information
- Received July 12, 2019
- Revision received October 23, 2019
- Accepted November 5, 2019
- Published online December 21, 2019.
- aDepartment of Nuclear Medicine, Hannover Medical School, Hannover, Germany
- bDivision of Molecular and Translational Cardiology, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
- ↵∗Address for correspondence:
Dr. Frank M. Bengel, Hannover Medical School, Department of Nuclear Medicine, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.
• Novel cardiovascular therapies increasingly modify molecular targets that may be heterogeneously expressed by patients.
• Molecular imaging provides tissue-level information on target expression and drug delivery to guide therapeutic intervention.
• Implementing molecular imaging approaches may stratify patient risk and optimize therapeutic delivery to enhance repair.
As therapeutic approaches have evolved from exogenous bone marrow cell delivery to pharmacological stimulation of endogenous repair, so too has imaging of cardiac repair made significant strides forward. Evaluation of functional outcome remains a staple of noninvasive clinical imaging, which can robustly quantify contractile function, perfusion, and tissue viability. Direct labeling of cells or other novel therapeutics visualizes the whole-body distribution and pharmacokinetics of the therapeutic agent, providing insights into retention, targeting, and drug-tissue interactions. And finally, targeted molecular imaging agents are emerging that may be specifically coupled to drugs targeting the same pathway. This approach enables interrogation of temporal and spatial changes at the molecular level underlying tissue degeneration and regeneration, which facilitates accurate patient selection and timing for therapeutic intervention, as exemplified by recent efforts focusing on the role of inflammation in cardiac repair. The concept of image-guided repair carves out an important and evolving niche for molecular imaging in cardiovascular medicine, with the potential not only to predict outcomes but also to improve patient stratification and progress toward personalized reparative therapy.
This work was supported by Deutsche Forschungsgemeinschaft (KFO311). Ms. Hess has received a stipend from Studienstiftung des deutschen Volkes. Dr. Wollert has filed a patent application and signed a licensing contract covering the therapeutic use of bone marrow cell–derived paracrine factors in cardiovascular disease. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 12, 2019.
- Revision received October 23, 2019.
- Accepted November 5, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.